India's Sun Pharma aims to launch its obesity drug in five years, managing director says
India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes drug in the next four to five years, Managing Director Dilip Shanghvi said on Friday.
Indian Billionaire Dilip Shanghvi’s Sun Pharma To Buy U.S. Cancer Drug Maker For $355 Million
Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and oncology company Checkpoint Therapeutics for $355 million to bolster the Mumbai-based company’s drug portfolio.
NS Pharma, a subsidiary of Nippon Shinyaku Co., announced that acceptance has been received by Capricor Therapeutics (CAPR) from the U.S. FDA ...
The FDA has approved a new therapy for the rare muscle wasting disease Duchenne muscular dystrophy (DMD) as Japan’s NS Pharma takes on Sarepta and its controversially approved rival. NS Pharma ...
Hosted on MSN9d
QNRX: More Positive Data Supporting Efficacy of QRX003 for NS; Campaign to Raise Awareness of the DiseaseQNRX READ THE FULL QNRX RESEARCH REPORT Positive interim clinical data Quoin Pharmaceuticals (NASDAQ:QNRX) is a clinical stage, specialty pharmaceutical company that focuses on developing treatments ...
TEL AVIV, Israel, Feb. 27, 2025 /PRNewswire/ -- Nasus Pharma Ltd. ("Nasus Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on developing needle-free, powder-based ...
The Japanese group’s NS Pharma subsidiary has revealed that Viltepso (viltolarsen) missed its primary objective in the confirmatory RACER53 trial, and was unable to distinguish itself from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback